P
Peter Lange
Researcher at University of Copenhagen
Publications - 488
Citations - 26426
Peter Lange is an academic researcher from University of Copenhagen. The author has contributed to research in topics: COPD & Population. The author has an hindex of 73, co-authored 465 publications receiving 23594 citations. Previous affiliations of Peter Lange include Gentofte Hospital & Aarhus University.
Papers
More filters
Journal ArticleDOI
A 15-year follow-up study of ventilatory function in adults with asthma.
TL;DR: Data from a longitudinal epidemiologic study of the general population in a Danish city, the Copenhagen City Heart Study, is used to analyze changes over time in the forced expiratory volume in one second (FEV1) in adults with self-reported asthma and adults without asthma.
Journal ArticleDOI
Regular physical activity reduces hospital admission and mortality in chronic obstructive pulmonary disease: a population based cohort study
TL;DR: The recommendation that COPD patients be encouraged to maintain or increase their levels of regular physical activity should be considered in future COPD guidelines, since it is likely to result in a relevant public health benefit.
Journal ArticleDOI
Prognostic value of nutritional status in chronic obstructive pulmonary disease
TL;DR: It is concluded that low BMI is an independent risk factor for mortality inSubjects with COPD, and that the association is strongest in subjects with severe COPD.
Journal ArticleDOI
Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial
Jøorgen Vestbo,Jøorgen Vestbo,Torben Søorensen,Peter Lange,Peter Lange,Anders Brix,Piero Torre,Kaj Viskum +7 more
TL;DR: Inhaled budesonide was of no clinical benefit in COPD patients recruited from the general population by screening and the role of long-term inhaled corticosteroids in the treatment of mild to moderate COPD is questioned.
Journal ArticleDOI
Once-Daily Single-Inhaler Triple versus Dual Therapy in Patients with COPD
David A. Lipson,Frank Barnhart,Noushin Brealey,Jean Brooks,Gerard J. Criner,Nicola C. Day,Mark T. Dransfield,David M.G. Halpin,MeiLan K. Han,C. Elaine Jones,Sally Kilbride,Peter Lange,David A. Lomas,Fernando J. Martinez,Dave Singh,Maggie Tabberer,Robert A. Wise,Steven Pascoe +17 more
TL;DR: Triple therapy with fluticasone furoate, umeclidinium, and vilanterol resulted in a lower rate of moderate or severe COPD exacerbations than flutic asonefuroate–vilanterol or u meclid inium–vilAnterol in this population.